RxDoctor Payments Data

Theodore Gray, MD

Hematology & Oncology · Hickory, NCNPI 1730199480

Payments from drug & device makers

$21,219in general payments, 2019–2025

Across 1,195 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$1K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Genentech USA, Inc.$1K
  • Johnson & Johnson$956
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$20,86698%
  • Education$3532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)89$1,658
Novartis80$1,425
Pfizer81$1,164
E.r. Squibb & Sons, L.L.C.69$1,126
Genentech USA, Inc.66$1,027
Johnson & Johnson55$956
Merck53$947
Eisai Inc.44$804
Sanofi37$785
Daiichi Sankyo Inc.36$737
Incyte Corporation40$734
Exelixis Inc.37$567
Amgen34$542
Seagen Inc.28$498
Bristol Myers Squibb22$400
Bayer20$397
Takeda Pharmaceuticals U.S.A., Inc.20$359
GSK19$352
Gilead(2 entities)19$336
Array Biopharma Inc19$285
AVEO Pharmaceuticals, Inc.11$283
Pharmacyclics LLC, An Abbvie Company13$253
Sobi, Inc10$251
Lilly USA, LLC15$239
Servier Pharmaceuticals LLC12$219
Puma Biotechnology, Inc.12$207
Jazz Pharmaceuticals Inc.11$199
AbbVie9$167
Astellas Pharma US Inc10$163
Beone Medicines USA, Inc.8$161
Taiho Oncology, Inc.8$155
Genmab U.S., Inc.8$155
Deciphera Pharmaceuticals Inc.7$145
Karyopharm Therapeutics Inc.6$139
EMD Serono, Inc.6$127
ADC Therapeutics America, Inc.8$126
Coherus Oncology, Inc.5$124
Regeneron Healthcare Solutions, Inc.6$123
Ipsen Biopharmaceuticals, Inc6$120
Boehringer Ingelheim7$110
Beigene USA, Inc.7$104
Sun Pharmaceutical Industries Inc.5$95
Novocure Inc.5$91
Myriad Genetic Laboratories, Inc.2$90
Adaptive Biotechnologies Corporation5$88
Secura Bio, Inc.6$86
Organon5$84
Acrotech Biopharma Inc.4$82
Mylan Institutional Inc.5$81
Springworks Therapeutics, Inc.4$79
Stemline Therapeutics Inc.4$79
Octapharma USA, Inc.1$77
Geron Corporation3$74
Agios Pharmaceuticals, Inc.4$70
Tersera Therapeutics LLC5$67
Clovis Oncology, Inc.5$62
Pharmaessentia USA Corporation3$62
Global Blood Therapeutics, Inc.4$57
Pharmacosmos Therapeutics Inc.3$57
Epizyme, Inc.4$56

How this compares

$21,219 in reported general payments places this provider in the 60th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,411,047
Medicare patients
523
Services billed
77,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$158

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →